21 april 2012: ik heb enkele veranderingen en aanpassingen gemaakt in de links in onderstaand artikel en onderaan een referentielijst toegevoegd van studies gedaan met Q-10

16 oktober 2002: Bron: Nature

Q-10, een natuurlijk voedingssupplement zorgt voor een grote afremming van het ziekteproces van de ziekte van Parkinson (40% verschil met controlegroep), blijkt uit een gerandomiseerde driejarige studie onder 80 patiënten aan de universiteit van Californië. Nu zult u zeggen maar dat is nog geen kanker, maar Q-10 wordt algemeen beschouwd als een sterke anti-oxidant, een kankerremmer die zowel preventief als aanvullend in een behandeling voor een positief effect zorgt. Lees enkele studies met Q-10 op pagina literatuurlijst van arts-bioloog Drs. E. Valstar of lees het referentieschema van de positieve effecten van bepaalde voedingsupplementen waaronder Q-10 in een behandeling van kanker. En de ziekte van Parkinson wordt ook algemeen gezien als een degeneratieve ziekte zoals ook kanker. Hieronder het persbericht over Q-10 bij de ziekte van Parkinson zoals gemeld door Nature. Valstar zegt: Overigens herhaal ik de waarschuwing zoals ook Nature doet, neem niet zonder consult zomaar een bepaalde hoeveelheid Q-10, maar consulteer altijd een orthomoleculaire arts voor de juiste dosering en eventuele contra-indicaties. Adresgegevens van goed gekwalificeerde orthomoleculaire artsen staan op pagina nuttige adressen.

 

d.d. 15 oktober 2002, bron Nature: An over-the-counter dietary pill may slow the brain deterioration seen in Parkinson's disease, researchers have announced1. But patients are being warned not to head for the drugstore just yet.

A dose of the supplement, coenzyme Q10, stalls the onset of some of the movement problems that accompany the disorder, the American Neurological Association meeting will hear today. "It didn't stop progression but it did reduce it," says Clifford Shults of the University of California, San Diego, who led the three-year pilot study.

Existing treatments for the disease relieve the symptoms but do not treat the cause: the breakdown of the nerves in the brain that make the neurotransmitter dopamine. Finding a drug that prevents this decay "is at the centre of everyone's radar screen", says Bill Langston of the Parkinson's Institute in Sunnyvale, California.

The findings of Shults's team are some of the first evidence for such a 'neuro-protective' agent. But experts stress that another large-scale trial will be required before doctors can start recommending daily supplements. "It would be premature to suggest to patients that they should take high levels of Q10," says Shults.

Because the enzyme is already available in drugstores as a dietary supplement, there are concerns that patients might start popping pills prematurely. "An unsuspecting public will be encouraged to buy it without any scientific evidence," warns Parkinson's researcher Warren Olanow of Mount Sinai School of Medicine in New York.

Parkinson's affects roughly a million people in the United States, causing tremors and slowing movement.

Q tip

Some Parkinson's patients have low levels of coenzyme Q10 and scientists hypothesized that this may contribute to nerve degeneration, prompting the trial. The enzyme normally dwells in mitochondria, the power generators of cells. It also acts as an antioxidant, stopping the production of damaging molecules called free radicals.

Shults and his colleagues treated 80 patients in their early 60s who showed initial signs of the disease. The patients received either a daily placebo or 300, 600 or 1,200 milligrams of coenzyme Q10, and were monitored over 16 months or until their symptoms required treatment with conventional dopamine therapy.

The condition of patients taking 1,200 milligrams worsened 40% less over time than that of patients taking the placebo, according to a scale that measures the severity of Parkinson's symptoms. For example, the patients might not need help in dressing themselves, explains Shults. Those taking the lower doses were helped to a lesser extent.

But some experts have voiced concerns over the trial. Looking at symptoms is only an indirect measure of nerve-cell damage, points out Olanow. The enzyme could simply be relieving the symptoms rather than preventing the disease. The trial did not actually delay the time at which patients needed treatment.

The US National Institutes of Health are currently deciding which potential neuro-protective agents to fund in large-scale clinical trials. Other potential treatments include anti-inflammatory drugs. "The field is flush with possible candidates," says Olanow. "The problem is to prove they work."


References
Shults, C. et al. Effects of coenzyme Q10 in early Parkinson disease. Archives of Neurology, 59, 1541 - 1550, (2002). |Article|

 

References
  • Kessenbrock K, Plaks V, Werb Z. Bicknell R: Matrix Metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67. doi: 10.1016/j.cell.2010.03.015. [PMC free article] [PubMed] [Cross Ref]
  • Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287–97. doi: 10.1200/JCO.2009.23.5556. [PMC free article] [PubMed] [Cross Ref]
  • Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010;28:661–9. doi: 10.3109/07357901003735634. [PubMed] [Cross Ref]
  • Ala-aho R, Kähäri VM. Collagenases in cancer. Biochimie. 2005;87:273–86. doi: 10.1016/j.biochi.2004.12.009. [PubMed] [Cross Ref]
  • Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001;3:323–7. doi: 10.1186/bcr315. [PMC free article] [PubMed] [Cross Ref]
  • Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006;25:695–705. doi: 10.1007/s10555-006-9037-8. [PubMed] [Cross Ref]
  • Shekelle P, Hardy ML, Coulter I, Udani J, Spar M, Oda K. Effect of the supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer. Evid Rep Technol Assess (Summ) 2003;75:1–3. [PubMed]
  • Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clin Biochem. 2007;40:623–8. doi: 10.1016/j.clinbiochem.2007.02.003. [PubMed] [Cross Ref]
  • Adhikary A, Mohanty S, Lahiry L, Hossain DM, Chakraborty S, Das T. Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett. 2010;584:7–14. doi: 10.1016/j.febslet.2009.10.081. [PubMed] [Cross Ref]
  • Chao HP, Kuo CD, Chiu JH, Fu SL. Andrographolide Exhibits Anti-Invasive Activity against Colon Cancer Cells via Inhibition of MMP2 Activity. Planta Med. 2010. in press . [PubMed]
  • Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. Mitochondrion. 2007. pp. S41–50. Epub 2007 Mar 16. [PubMed] [Cross Ref]
  • Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition. 2010;26:250–4. doi: 10.1016/j.nut.2009.08.008. [PubMed] [Cross Ref]
  • Portakal O, Ozkaya O, Erden Inal M, Bozan B, Kosan M, Sayek I. coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000;33:279–284. doi: 10.1016/S0009-9120(00)00067-9. [PubMed] [Cross Ref]
  • Hertz N, Lister RE. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. J Int Med Res. 2010;38:293.
  • Sachdanandam P. Antiangiogenic and hypolipidemic activity of coenzyme Q10 supplementation to breast cancer patients undergoing Tamoxifen therapy. Biofactors. 2008;32:151–9. doi: 10.1002/biof.5520320118. [PubMed] [Cross Ref]
  • Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull. 2007;30:367–70. doi: 10.1248/bpb.30.367. [PubMed] [Cross Ref]
  • Premkumar VG, Yuvaraj S, Sathish S, Shanthi P, Sachdanandam P. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul Pharmacol. 2008;48:191–201. doi: 10.1016/j.vph.2008.02.003. [PubMed] [Cross Ref]
  • Rusciani L, Proietti I, Rusciani A, Paradisi A, Sbordoni G, Alfano C. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol. 2006;54:234–41. doi: 10.1016/j.jaad.2005.08.031. [PubMed] [Cross Ref]
  • Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol. 1999;12:669–74. [PubMed]
  • Cheng CJ, Lin YC, Tsai MT, Chen CS, Hsieh MC, Chen CL. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res. 2009;69:3634–41. doi: 10.1158/0008-5472.CAN-08-3615. [PubMed] [Cross Ref]
  • Bogani P, Canavesi M, Hagen TM, Visioli F, Bellosta S. Thiol supplementation inhibits metalloproteinase activity independent of glutathione status. Biochem Biophys Res Commun. 2007;363:651–5. doi: 10.1016/j.bbrc.2007.09.018. [PubMed] [Cross Ref]
  • Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med. 1999;27:922–35. doi: 10.1016/S0891-5849(99)00176-8. [PubMed] [Cross Ref]
  • Pei P, Horan MP, Hille R, Hemann CF, Schwendeman SP, Mallery SR. Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention. Free Radic Biol Med. 2006;41:1315–24. doi: 10.1016/j.freeradbiomed.2006.07.014. [PMC free article] [PubMed] [Cross Ref]
  • Das S, Banerji A, Frei E, Chatterjee A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008;82:467–76. doi: 10.1016/j.lfs.2007.12.013. Epub 2007 Dec 27. [PubMed] [Cross Ref]
  • Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, Chen W, Knapp W, Zlabinger GJ. A microplate assay for the detection of oxidative products using 2',7'-dichlorofluorescin-diacetate. J Immunol Methods. 1992;156:39–45. doi: 10.1016/0022-1759(92)90008-H. [PubMed] [Cross Ref]
  • Factor VM, Kiss A, Woitach JT, Wirth PJ, Thorgeirsson SS. Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem. 1998;273:15846–53. doi: 10.1074/jbc.273.25.15846. [PubMed] [Cross Ref]
  • Kupai K, Szucs G, Hajdu I, Csonka C, Csont T. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods. 2010;61:205–9. doi: 10.1016/j.vascn.2010.02.011. [PubMed] [Cross Ref]
  • Khorramizadeh MR, Pezeshki M, Ghahary A, Zeraati H, Berahmeh A. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters. Int J Urol. 2005;12:637–43. doi: 10.1111/j.1442-2042.2005.01094.x. [PubMed] [Cross Ref]
  • Das S, Banerji A, Frei E, Chatterjee A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008;82:467–76. doi: 10.1016/j.lfs.2007.12.013. [PubMed] [Cross Ref]
  • Ortega A, Ferrer P, Carretero J, Obrador E, Asensi M, Pellicer JA. Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium. J Biol Chem. 2003;278:39591–9. doi: 10.1074/jbc.M303753200. [PubMed] [Cross Ref]
  • Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med. 2004;37:768–84. doi: 10.1016/j.freeradbiomed.2004.06.008. [PubMed] [Cross Ref]
  • Sandhya T, Mishra KP. Cytotoxic response of breast cancer cell lines, MCF 7 and T 47 D to triphala and its modification by antioxidants. Cancer Lett. 2006;238:304–13. doi: 10.1016/j.canlet.2005.07.013. [PubMed] [Cross Ref]
  • Voronkina IV, Kirpichnikova KM, Smagina LV, Gamaliĭ IA. Changes in matrix metalloproteinases activities in normal and transformed mouse fibroblasts under effect of antioxidants. Tsitologiia. 2008;50:877–81. [PubMed]
  • Bogani P, Canavesi M, Hagen TM, Visioli F, Bellosta S. Thiol supplementation inhibits metalloproteinase activity independent of glutathione status. Biochem Biophys Res Commun. 2007;363:651–5. doi: 10.1016/j.bbrc.2007.09.018. [PubMed] [Cross Ref]
  • Tyagi SC, Kumar S, Borders S. Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem. 1996;61:139–51. doi: 10.1002/(SICI)1097-4644(19960401)61:1<139::AID-JCB15>3.0.CO;2-J. [PubMed] [Cross Ref]
  • Lazo JS, Kuo SM, Woo ES, Pitt BR. The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem Biol Interact. 1998;111-112:255–262. doi: 10.1016/S0009-2797(97)00165-8. [PubMed] [Cross Ref]
  • Brenneisen P, Briviba K, Wlaschek M, Wenk J, Scharffetter-Kochanek K. Hydrogen peroxide (H2O2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts. Free Radic Biol Med. 1997;22:515–24. doi: 10.1016/S0891-5849(96)00404-2. [PubMed] [Cross Ref]
  • Wenk J, Brenneisen P, Wlaschek M, Poswig A, Briviba K, Oberley TD. Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrix-degrading metalloprotease-1. J Biol Chem. 1999;274:25869–76. doi: 10.1074/jbc.274.36.25869. [PubMed] [Cross Ref]
  • Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. 2008;32:179–83. doi: 10.1002/biof.5520320121. [PubMed] [Cross Ref]
  • Factor VM, Kiss A, Woitach JT, Wirth PJ, Thorgeirsson SS. Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem. 1998;273:15846–53. doi: 10.1074/jbc.273.25.15846. [PubMed] [Cross Ref]
  • Linnane AW, Kios M, Vitetta L. Coenzyme Q10 - its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion. 2007. pp. S51–61. Epub 2007 Mar 30. [PubMed] [Cross Ref]
  • Abbasi N, Khaghani S, Sharif-Tabrizi A, Farzami B, Vardasbi S, Bahar M. et al. Comparison of Lipoamide dehydrogenase activity in HL-60 Leukemia cells and normal lymphocyte. Acta Medica Iranica. 2007;45:282–284.


Plaats een reactie ...

Reageer op "Q-10 werkt ook in het afremmen van de ziekte van Parkinson - 40 procent meer remming t.o.v. controlegroep - blijkt uit driejarige gerandomiseerde studie."


Gerelateerde artikelen
 

Gerelateerde artikelen

Q-10 werkt ook in het afremmen >> Q-10 in de vorm van Ubiquinone >> Q-10: Het natuurlijke niveau >>